Mottagning för särskild vård, sprutbytet, Husläkarmottagning för hemlösa
Uppsala, Uppland, 75323, Sweden
NCT Number: NCT05737550
This will be a pre-market, explorative, early feasibility, pilot, controlled clinical investigation designed to collect initial clinical data for Previct Drugs.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Uppsala, Uppland, 75323, Sweden
This second early feasibility study will give valuable information on the usability of Previct Drugs once being used in the intended population, i.e, patients with confirmed Substance Use Disorder (SUD). It will also give valuable information on the feasibility of Previct drugs function to measure pupils and eye movements in this population including evaluating the safety when using the device.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Previct Drugs is a new non CE-marked eHealth system intended to be used for future monitoring and treatment of patients with substance use disorder (SUD). Previct Drugs consists of an application (app) to be installed on a smartphone, a web-based careportal to be accessed from a computer by the healthcare professional for administration and access of registered data, and a database for storage, handling, and analysis of reported data. Previct Drugs is intended to be used by healthcare professionals and patients within treatment of SUD.
Time frame: Day 0 (Visit 1)
Observation of a study subject during a test with Previct Drugs through answering a usability questionnaire consisting of 18 usability questions.
Question 1. Please evaluate the study subject's ability to use the mobile phone?
Response options:
Time frame: Day 0 (Visit 1)
Observation of a study subject during a test with Previct Drugs through answering a usability questionnaire consisting of 18 usability questions.
Question 2. How did you perceive the study subject's ability to follow the instructions given by Previct Drugs?
Response options:
Time frame: Day 0 (Visit 1)
Observation of a study subject during a test with Previct Drugs through answering a usability questionnaire consisting of 18 usability questions.
Question 4. How did the study subject experience to put him/herself in the right position to be able to start a test?
Response options:
Time frame: Day 0 (Visit 1)
Observation of a study subject during a test with Previct Drugs through answering a usability questionnaire consisting of 18 usability questions.
Question 6. How would you evaluate the study subject's ability to perform a Cross-eyes test?
Response options:
Time frame: Day 0 (Visit 1)
Observation of a study subject during a test with Previct Drugs through answering a usability questionnaire consisting of 18 usability questions.
Question 8. How would you evaluate the study subject's ability to perform a Nystagmus test?
Response options:
Time frame: Day 0 (Visit 1)
Observation of a study subject during a test with Previct Drugs through answering a usability questionnaire consisting of 18 usability questions.
Question 10. How would you evaluate the study subject's ability to perform a Contraction Test?
Response options:
Time frame: Day 0 (Visit 1)
Observation of a study subject during a test with Previct Drugs through answering a usability questionnaire consisting of 18 usability questions.
Question 12. How did the study subject experience keeping the phone still during the test?
Response options:
Time frame: Day 0 (Visit 1)
Observation of a study subject during a test with Previct Drugs through answering a usability questionnaire consisting of 18 usability questions.
Question 14. In addition to the basic instructions, did the study subject need additional support performing tests with Previct Drugs?
Response options:
Time frame: Day 0 (Visit 1)
Observation of a study subject during a test with Previct Drugs through answering a usability questionnaire consisting of 18 usability questions.
Question 16. Was the study subject able to perform the test after receiving additional support?
Response options:
Time frame: Day 0 (Visit 1)
Observation of a study subject during a test with Previct Drugs through answering a usability questionnaire consisting of 18 usability questions.
Question 17. How many efforts did it take the study subject to perform test with Previct Drugs?
Response options:
Time frame: Day 0 (Visit 1)
Observation of a study subject during a test with Previct Drugs through answering a usability questionnaire consisting of 18 usability questions.
Question 18. How likely do you think it is that the study subject will be able to perform tests with Previct Drugs without assistance in a home environment?
Response options:
Time frame: Up to 4 weeks post baseline
The fraction of collected pupillometry data from the mobile phone application, which can be transformed into pre-defined key features using native pupillograms, i.e. proportion of successful tries. For each of the measurements pupillary light reflex (PLR), non-convergence (NC), horizontal nystagmus (NY), tremor (TR), and redness (RED) the measurements quality control will approve the measurement or not using the native pupillogram. The proportion of approved measurements over all measurements will be calculated for each of the tests (PLR, NC, NY, TR, RED). The results includes all tries performed, including tries in two ambient light conditions. In case one test is not approved by the application's quality control, the application will instruct the subject to re-do the test. The number tests are thus more than the number of subjects included in the study, and can differ between the different test types.
Time frame: Up to 4 weeks post baseline
The fraction of collected pupillometry data from the mobile phone application, which can be transformed into pre-defined key features using refined pupillograms, i.e. proportion of successful tries. For each of the measurements pupillary light reflex (PLR), non-convergence (NC), horizontal nystagmus (NY), tremor (TR), and redness (RED) the measurements quality control will approve the measurement or not using the refined pupillogram. The proportion of approved measurements over all measurements will be calculated for each of the tests (PLR, NC, NY, TR, RED). The results includes all tries performed, including tries in two ambient light conditions. In case one test is not approved by the application's quality control, the application will instruct the subject to re-do the test. The number tests are thus more than the number of subjects included in the study, and can differ between the different test types.
Kontigo Care AB
Industry
A Second Explorative Pilot Study Evaluating Usability and Functionality of a New Mobile Phone Application Measuring Eye Parameters of Eyes in Patients With Confirmed Substance Use Disorder (SUD)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00787423
Chemically-Induced Disorders, Drug Abuse
Baltimore, Maryland, United States
View Trial DetailsNCT01036685
Chemically-Induced Disorders, Drug Abuse
Baltimore, Maryland, United States
View Trial DetailsNCT03918850
Chemically-Induced Disorders, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Jacksonville, Florida, United States
View Trial DetailsNCT07552623
Chemically-Induced Disorders, Disease Attributes
Lahore, Punjab Province, Pakistan
View Trial Details